Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01457872
Other study ID # MATRIS
Secondary ID
Status Completed
Phase N/A
First received October 18, 2011
Last updated November 24, 2014
Start date October 2011
Est. completion date April 2013

Study information

Verified date November 2014
Source Region Skane
Contact n/a
Is FDA regulated No
Health authority Sweden: Regional Ethical Review Board
Study type Interventional

Clinical Trial Summary

This study aims to study and implement active referral of heroin users from a syringe exchange programme to evidence-based treatment for heroin addiction. Patients are randomized to either a strength-based case management intervention or a control group, while both groups receive referral to medical investigation for inclusion in substitution treatment for heroin addiction. The hypothesis is that syringe exchange can be used for referral to effective treatment, and that a strength-based intervention can increase the number of patients who are successfully referred and enter treatment.


Description:

Patients attending the syringe exchange programme of Malmö, Sweden, and who are using heroin as their primary drug of abuse and who live in the catchment area of Malmö Addiction Centre, will be addressed, and patients willing to participate will undergo a baseline interview and will be referred to medical examination for decision to start substitution treatment to treat heroin dependence. Half of patients will be randomized to a strength-based case management intervention, hypothesized to facilitate treatment entry, and half of patients will be randomized to a control condition involving only referral.

The study will measure the number of patients who successfully accept referral and initiate substitution treatment for heroin dependence, comparing patients in intervention arm to patients in the control condition (RCT design). Also, as a secondary outcome measure, retention and treatment outcome (substance use and clinical characteristics) will be compared between the two groups. In addition, this study will enable a number of sub-analyses aiming to increase knowledge about heroin addicts' detailed substance use pattern and clinical characteristics. Patients will be followed with respect to retention, substance use and clinical picture for three years.


Recruitment information / eligibility

Status Completed
Enrollment 79
Est. completion date April 2013
Est. primary completion date April 2013
Accepts healthy volunteers No
Gender Both
Age group 20 Years and older
Eligibility Inclusion Criteria:

- Registered at syringe exchange programme of Malmö

- Primary drug heroin

- Heroin dependence

- Living in catchment area for substitution treatment of Addiction Centre Malmö

Exclusion Criteria:

- Inability to understand consent and information

- Unstable psychiatric condition making treatment regulations impossible

- Pregnancy

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Behavioral:
Strength-based case management
Strength-based case management
Control condition - referral only
Referral only

Locations

Country Name City State
Sweden Malmö Addiction Centre, Malmö University Hospital entrance 90 Malmö

Sponsors (2)

Lead Sponsor Collaborator
Region Skane Swedish Council for Working Life and Social Research

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Treatment entry in substitution treatment at two time points - directly after referral and after up to 3 months Percentage of patients successfully referred for examination and start of substitution treatment. This is measured at two time points, at 10 days post-referral when the medical examination is carried out (the percentage of patients who successfully show up) and subsequently the patients will be followed up to three months post-referral with respect to actual initiation of medication. At medical examination after 10 days, and subsequently for up to 3 months No
Secondary Retention and treatment outcome in substitution treatment Percentage of patients remaining in treatment. Treatment outcome including decrease in substance use and improvement in clinical picture. 3, 6, 12, 24, 26 months No
See also
  Status Clinical Trial Phase
Recruiting NCT05660434 - Using Aromatherapy in Substance Use Disorder N/A
Recruiting NCT05338268 - Substance Use and Loneliness N/A
Completed NCT03954184 - E-health Implementation (Iowa) N/A
Completed NCT04098614 - Barriers to Substance Use Disorder Recovery N/A
Completed NCT03590106 - Cardiac Surgery Peer Recovery Support Program N/A
Recruiting NCT05118204 - Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization Phase 4
Recruiting NCT06273228 - Parenting Young Children in Pediatrics N/A
Recruiting NCT05327504 - Written Exposure Therapy for Veterans With SUD and PTSD N/A
Terminated NCT03517111 - The Impact of a Parenting Intervention on Latino Youth Health Behaviors N/A
Completed NCT04284813 - Families With Substance Use and Psychosis: A Pilot Study N/A
Completed NCT04401215 - Technologically-Augmented Referrals to Mitigate Addiction Consequences N/A
Not yet recruiting NCT06187701 - Co-Active Therapeutic Theatre (Co-ATT) for Dual-Diagnosis Patients N/A
Recruiting NCT04296604 - Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations N/A
Active, not recruiting NCT02382042 - Intensive Referral Intervention to Improve Substance Use Disorder Treatment Outcomes Among Rural and Highly Rural Veterans N/A
Terminated NCT01356667 - Drum-Assisted Therapy for Native Americans N/A
Completed NCT01237366 - Study Targeting Affect Regulation Phase 1/Phase 2
Completed NCT00708890 - Twelve Step Based Self-help Groups for Substance Related Disorders N/A
Active, not recruiting NCT04048850 - Zepatier in Patients With Substance Use
Recruiting NCT05976646 - Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion Phase 1/Phase 2
Recruiting NCT06094972 - The Effectiveness of A-CRA in Compulsory Institutional Care for Youth N/A